37. Generalised pustular psoriasis Clinical trials / Disease details


Clinical trials : 74 Drugs : 53 - (DrugBank : 20) / Drug target genes : 20 - Drug target pathways : 101

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004021-33-GB
(EUCTR)
04/05/201820/12/2017To Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular PsoriasisA Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis - ANB019-002 - Generalized Pustular Psoriasis Generalized Pustular Psoriasis (GPP)
MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Psoriasis pustular;System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
Other descriptive name: Alvarez 2
AnaptysBio Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
10 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;United Kingdom